Probiotic strain with direct butyrate production launched in North American market

After achieving self-affirmed GRAS status earlier this year, the probiotic CLB101 is entering North American retail markets. In November 2025, Maypro and biotechnology company ClostraBio announced they have partnered to launch CLB101 to the North American retail market.¹ The probiotic is developed from Anaerostipes caccae and is capable of producing the short-chain fatty acid butyrate, which supports the intestinal lining, strengthens the gut barrier integrity, and helps maintain microbiome diversity and immune balance. In comparison to probiotics that influence butyrate levels, the butyrate production is continuously produced through CLB101 metabolizing prebiotic fibers and bacterial byproducts.

The benefits of butyrate include stimulating T-cell activity, which can calm inflammation in the gut, supporting beneficial anaerobes, and promoting tight junction formation.

“A healthy gut begins with a healthy gut barrier,” stated Abhijit Natu, vice president of sales and marketing at Maypro. “By supporting beneficial bacteria, strengthening the intestinal lining, and addressing factors that contribute to gut inflammation, CLB101 represents a keystone probiotic strain for next-generation gut health formulations.”

CLB101 also supports digestive comfort and regularity.

“At ClostraBio, our mission is to leverage a science driven, multi-pronged approach to address conditions of the lower gut, using novel next-generation probiotics,” stated Ritu Shah, CEO of ClostraBio. “CLB101 is the first probiotic designed to mimic the body’s natural butyrate cycle, offering a new frontier in gut integrity and immune support.”

The ingredient is available in a once-daily capsule format. The official launch took place at SupplySide Global 2025.

Self-affirmed GRAS status of CLB101

Earlier this year, Clostrabio announced the self-affirmed Generally Recognized as Safe (GRAS) status of CLB101.² A panel had reviewed the safety data of toxicology studies, genomic characterization, and more, plus the manufacturing process.

“Receiving GRAS status marks a critical milestone for ClostraBio and validates the safety of CLB101 as we move towards commercial launch,” Shah had stated in the June 2025 press release. “This recognition reinforces our commitment to advancing safe, science-driven solutions that can help support gut health for the many people who are struggling today.”

Maypro partners with Tradichem

In October 2025, Maypro announced a distribution partnership with Tradichem Group, along with its subsidiaries Florida Human Nutrition and Tradichem Industrial Services.³ The partnership introduced the technologies Clonapure and Hipering to the North American Market.

Clonapure, created by Florida Human Nutrition, is a creatine complex intended to have rapid absorption and performance benefits, and contains “creatine monohydrate, phosphocreatine, and phosphate in precise ratios to optimize intracellular creatine replenishment, enhance ATP production, and support sustained energy, power, and endurance,” the press release explained. As creatine experiences growth beyond the sports nutrition category, Clonapure can also offer help for overall metabolic health, weight managements protocols, and muscle support.

The Hipering platform, designed by Tradichem Industrial Services, supports supplement manufacturing by turning fine powders to free-flowing, compressible granules, avoiding machine adhesion and poor flowability. It also enables tablet quality and clean label formulations by removing the need for excipients, fillers, and synthetic binders.

“Hipering modifies the physical properties of raw ingredients while maintaining purity and chemical integrity,” explained José Angel Maroñon, CEO of Tradichem Group. “Manufacturers can now achieve optimal production efficiency and product consistency without compromising on ingredient quality. Raw ingredients are transformed into a free-flowing, compressible form without the need for synthetic binders, fillers, or other excipients.”

References

1. Maypro. Maypro Partners with ClostraBio to Launch CLB101™. November 12, 2025. (Accessed 2025-12-05).
2. McEvoy, E. Probiotic strain from ClostraBio obtains self-affirmed GRAS status. July 30, 2025. https://www.nutritionaloutlook.com/view/probiotic-strain-from-clostrabio-obtains-self-affirmed-gras-status (Accessed 2025-12-05).
3. Colli, M. Maypro announces distribution partnership with Tradichem Group. October 1, 2025. https://www.nutritionaloutlook.com/view/maypro-announces-distribution-partnership-with-tradichem-group (Accessed 2025-12-05).